10:49 AM EDT, 09/11/2024 (MT Newswires) -- PharmAla Biotech Holdings ( MDXXF ) , in the research and manufacture of LaNeo MDMA and novel derivatives of MDMA (MDXX class molecules), reported Wednesday that it has been contracted as a supplier of MDMA to a clinical trial at Johns Hopkins Medicine.

"We're looking forward to continuing to provide exceptional service - as well as robust investigational drug product - to researchers in the US and around the world," said Nicholas Kadysh, CEO, PharmAla Biotech ( MDXXF ), in a statement. "Over the past month we have been in communication with a great number of researchers, and we believe that only PharmAla is in a position to fulfill the need for GMP MDMA that has met the quality standards set by regulators like FDA."

PharmAla will also present the data on its novel proprietary molecule, APA-01, as "Hot Topics" at the European Behavioural Pharmacology Society (EBPS) Workshop on September 26. The presentation will discuss results of PharmAla's pre-clinical animal research.

Price: 0.10, Change: +0.01, Percent Change: +11.76